{"brief_title": "Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer", "brief_summary": "The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.", "detailed_description": "Only patients with 0 to 1 performance status on the ECOG scale are eligible.", "condition": ["Advanced Non Small Cell Lung Cancer", "Failed Prior Chemotherapy"], "intervention_type": ["Drug"], "intervention_name": ["Tarceva (Trademark) (erlotinib HCl, OSI-774)"], "description": ["Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash"], "arm_group_label": ["1 erlotinib"], "criteria": "Inclusion Criteria: - Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological). - Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer. - Measurable disease per RECIST criteria. - Adequate bone marrow, hepatic and renal function. Exclusion Criteria: - Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years. - Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days. - Known hypersensitivity to minocycline. - History of serious cardiac disease that is not controlled. - Serious eye conditions. - Prior treatment with inhibitors of EGFR of any kind.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "OSI-774", "mesh_term": ["Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Erlotinib Hydrochloride"], "id": "NCT00072631"}